NCT00003190
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia treatment 3 completed NCT00112853
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 completed NCT00095797
XK469R in Treating Patients With Refractory Hematologic Cancer No drug interventions treatment 1 completed NCT02921061
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS treatment 1 / 2 completed NCT02583893
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia basic_science 2 completed NCT00602771
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia treatment 2 completed NCT02323607
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations treatment 1 completed NCT01907815
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia treatment 2 terminated NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction treatment 1 completed NCT01831232
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes treatment Not Available completed NCT00703300
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia treatment 1 completed NCT02144675
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia treatment 2 completed NCT01521936
Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy No drug interventions supportive_care 2 terminated NCT00093418
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia treatment 2 completed NCT02121418
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm treatment Not Available completed NCT00039117
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia treatment 1 completed NCT00003934
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia treatment 3 completed NCT00101296
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT02044796
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes treatment 1 / 2 completed NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant treatment 1 / 2 completed NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies treatment Not Available completed NCT00313586
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia treatment 2 completed NCT01141725
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS treatment 1 / 2 completed NCT00278330
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia treatment 1 completed NCT02381548
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia treatment 1 terminated NCT00098826
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes treatment 1 completed NCT01690065
Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML treatment 2 unknown_status NCT00352365
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia treatment 2 completed NCT00027820
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer treatment 1 / 2 completed NCT00305773
Vorinostat in Treating Patients With Acute Myeloid Leukemia treatment 2 completed NCT01101880
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm treatment 2 completed NCT00445744
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome treatment Not Available completed NCT03009240
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT01798901
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia treatment 1 completed NCT01804101
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia treatment Not Available completed NCT00027872
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia treatment 2 completed NCT01349972
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT01031368
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia treatment 1 completed NCT01801046
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia treatment 1 terminated NCT00459212
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia treatment 1 completed NCT02122081
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 1 completed NCT02093403
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia treatment 1 completed NCT01361464
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia treatment 2 completed NCT00795002
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT01307579
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia supportive_care 3 completed NCT01802333
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia treatment 3 completed NCT01876953
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia treatment 1 / 2 terminated NCT00673153
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia treatment 2 terminated NCT00008177
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes treatment 1 completed NCT01869777
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia No drug interventions diagnostic Not Available completed NCT01564277
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies treatment 2 terminated NCT01044745
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer treatment 2 terminated NCT00416598
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia treatment 2 completed NCT00462605
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia treatment 2 completed NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT01806571
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT00079378
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma treatment 1 completed NCT01822015
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 0 completed NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 1 completed NCT00357032
PXD101 in Treating Patients With Acute Myeloid Leukemia treatment 2 completed NCT01567059
Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 2 completed NCT01633099
Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients treatment 3 unknown_status NCT01130506
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT02581917
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia No drug interventions Not Available Not Available completed NCT02029417
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 terminated NCT00085124
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia treatment 3 completed NCT02105116
AML Therapy With Irradiated Allogeneic Cells treatment Not Available terminated NCT00016016
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia treatment 1 / 2 completed NCT01519596
Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy No drug interventions supportive_care Not Available completed NCT00006363
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia treatment 3 completed NCT01132586
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia treatment 1 completed NCT00096122
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia treatment 1 / 2 completed NCT02835222
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients treatment 2 recruiting NCT00742625
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia treatment 1 / 2 completed NCT00096148
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 terminated NCT00387426
Sunitinib in Treating Patients With Idiopathic Myelofibrosis treatment 2 terminated NCT02472626
6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 1 / 2 withdrawn NCT00407966
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 2 completed NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies supportive_care 2 completed NCT00383474
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase treatment 1 completed NCT00049582
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia treatment 1 terminated NCT01093573
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia treatment 1 / 2 completed NCT02634827
Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation treatment 2 terminated NCT00012376
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer treatment 1 completed NCT01849276
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML treatment 1 terminated NCT00275080
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia treatment 1 completed NCT00801489
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 2 recruiting NCT01839240
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia treatment 1 completed NCT02129101
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies treatment 1 completed NCT00492401
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia treatment 2 completed NCT01555268
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia treatment 1 completed NCT02159495
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm treatment 1 active_not_recruiting NCT02115295
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia treatment 2 recruiting NCT01260714
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia treatment 1 terminated NCT02096055
Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia treatment 2 completed NCT00475150
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome treatment 2 completed NCT02666950
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome treatment 2 completed NCT02085408
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia treatment 3 active_not_recruiting NCT00301938
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes treatment 1 completed NCT01041443
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes treatment 1 completed